Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin + paclitaxel versus cisplatin + paclitaxel as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
ChiCTR1900024987Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lobaplatin, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: overall survival. Started Dec 2018; status: recruiting.
02
Drugs
lobaplatinpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900024987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024987.